These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 12230706)

  • 1. Prostate cancer: metastatic.
    Michaelson D; Talcott J; Smith M
    Clin Evid; 2002 Jun; (7):804-11. PubMed ID: 12230706
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate cancer: metastatic.
    Michaelson MD; Talcott JA; Smith MR
    Clin Evid; 2002 Dec; (8):881-90. PubMed ID: 12603918
    [No Abstract]   [Full Text] [Related]  

  • 3. [Advanced prostatic carcinoma--which hormone therapy when?].
    Studer UE
    Urologe A; 1995 Sep; 34(5):361-6. PubMed ID: 7483151
    [No Abstract]   [Full Text] [Related]  

  • 4. [Renaissance of estrogen therapy in advanced prostate carcinoma?].
    Smith PH; Robinson MR
    Urologe A; 1995 Sep; 34(5):393-7. PubMed ID: 7483156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Metastatic prostate carcinoma].
    Smith MR; Kantoff P; Talcott J
    Praxis (Bern 1994); 2001 Sep; 90(38):1653-8. PubMed ID: 11675919
    [No Abstract]   [Full Text] [Related]  

  • 6. Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival.
    Bournakis E; Efstathiou E; Varkaris A; Wen S; Chrisofos M; Deliveliotis C; Alamanis C; Anastasiou I; Constantinides C; Bamias A; Dimopoulos MA
    Anticancer Res; 2011 Apr; 31(4):1475-82. PubMed ID: 21508406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal treatment of advanced disease: some newer aspects.
    Griffiths K; Eaton CL; Harper ME; Turkes A; Peeling WB
    Semin Oncol; 1994 Oct; 21(5):672-87. PubMed ID: 7939755
    [No Abstract]   [Full Text] [Related]  

  • 8. [Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status].
    Stege R; Carlström K; Hedlund PO; Pousette A; von Schoultz B; Henriksson P
    Urologe A; 1995 Sep; 34(5):398-403. PubMed ID: 7483157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer: improving the therapeutic index.
    Scher HI
    Semin Oncol; 1994 Oct; 21(5):688-93. PubMed ID: 7524157
    [No Abstract]   [Full Text] [Related]  

  • 10. The questionable use of hormone therapy in advanced carcinoma of the prostate.
    Murphy GP; Slack NH
    Urol Clin North Am; 1980 Oct; 7(3):631-8. PubMed ID: 6161459
    [No Abstract]   [Full Text] [Related]  

  • 11. [First national Enantone Symposium. Progress in therapy of prostatic cancer. Multicenter study: long-term follow-up].
    Fornara P
    Urologe A; 1991 May; 30(3 Suppl):10-2. PubMed ID: 1746070
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic model of event-free survival for patients with androgen-independent prostate carcinoma.
    Shulman MJ; Benaim EA
    Cancer; 2005 Jun; 103(11):2280-6. PubMed ID: 15844202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Complex treatment of prostate cancer patients].
    Sviridova TV; Dunchik VN; Mardynskiĭ IuS; Tsodikova LB
    Urol Nefrol (Mosk); 1984; (2):9-13. PubMed ID: 6719653
    [No Abstract]   [Full Text] [Related]  

  • 14. Experimental and theoretical basis for hormonal treatment of prostatic cancer.
    Carter HB; Isaacs JT
    Semin Urol; 1988 Nov; 6(4):262-8. PubMed ID: 3068765
    [No Abstract]   [Full Text] [Related]  

  • 15. Carcinoma of the prostate: reasons for endocrine treatment prior to symptomatic metastases.
    Chisholm GD
    Prog Clin Biol Res; 1990; 359():1-6; discussion 15-24. PubMed ID: 2284285
    [No Abstract]   [Full Text] [Related]  

  • 16. The case for early combined hormonal and cytostatic treatment for metastatic prostatic carcinoma.
    Servadio C
    Prog Clin Biol Res; 1987; 243B():449-53. PubMed ID: 3659039
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessment of quality of life in patients with prostate cancer.
    Fosså SD; Aass N; Opjordsmoen S
    Semin Oncol; 1994 Oct; 21(5):657-61. PubMed ID: 7524156
    [No Abstract]   [Full Text] [Related]  

  • 18. Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen.
    Tomioka S; Shimbo M; Amiya Y; Nakatsu H; Murakami S; Shimazaki J
    Jpn J Clin Oncol; 2008 Jan; 38(1):36-42. PubMed ID: 18258713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Criteria for evaluating patient responses to treatment modalities for prostatic cancer.
    Slack NH; Murphy GP
    Urol Clin North Am; 1984 May; 11(2):337-42. PubMed ID: 6375069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone-refractory prostate cancer: what have we learned?
    Wirth MP
    BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.